Tesla sinks following reports that it is cutting car prices in China Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- BiondVax (BVXV) up 10% after additional results in a preclinical in vivo proof-of-concept study of its inhaled nanosized antibody COVID-19 therapy, namely that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax's NanoAb was below detectable levels and significantly less than the amount of virus detected in the placebo group
- Spruce Biosciences (SPRB) up 130% after entering into an exclusive licensing agreement for the development and commercialization of Spruce's product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia in Japan
- CytomX Therapeutics (CTMX) up 72% after the company and Moderna (MRNA) announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform
UP AFTER EARNINGS -
- Duck Creek Technologies (DCT) up 1%
- Aurinia Pharmaceuticals (AUPH) up 5%
- Aehr Test Systems (AEHR) up 16%
LOWER -
- Tesla (TSLA) down 7% after The Wall Street Journal reported that the company is cutting the prices of its Model 3 and Model Y cars sold in China after deliveries of its cars plunged in December
- Bed Bath and Beyond (BBBY) down another 12% after yesterday pre-announcing Q3 results and expressing doubts in the company's ability to continue as a going concern.
- Southwest (LUV) down 2% after reporting preliminary Q4 results and noting that it expects to report a net loss in Q4
- Novocure (NVCR) down 4% after Wells Fargo analyst Larry Biegelsen downgraded the stock to Equal Weight from Overweight with a price target of $107, up from $89
- Fate Therapeutics (FATE) down 58% after declining a proposal from Johnson & Johnson (JNJ) unit Janssen Biotech for continuation of the collaboration and option agreement between the parties on revised terms and conditions and, as a result, the agreement has been terminated and all collaboration activities will be wound down in the first quarter of 2023
Symbols:
BVXV SPRB CTMX DCT AUPH AEHR TSLA BBBY LUV NVCR - $118.46 /
+47.98 (+68.08%)
FATE MRNA JNJ Keywords: Fly Intel, Wall Street, Top Stories, Stocks